Granules India gains on getting USFDA`s nod for Gabapentin Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Granules India is currently trading at Rs. 272.00, up by 1.00 points or 0.37% from its previous closing of Rs. 271.00 on the BSE.
The scrip opened at Rs. 269.00 and has touched a high and low of Rs. 272.80 and Rs. 267.85 respectively. So far 9195 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 287.00 and Rs. 267.85 respectively. The current market cap of the company is Rs. 6559.36 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.41% and 29.56% respectively.
Granules India has received approval from US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 600 mg and 800 mg. It is bioequivalent to the reference listed drug product (RLD), Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC.
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults; and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.
Granules now have a total of 55 ANDA approvals from US FDA (53 Final approvals and 2 tentative approvals). The current annual U.S. market for Gabapentin Tablets is approximately $145 million.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
